Subscribe
shutterstock_1144555808_piotr_swat
Piotr Swat / Shutterstock.com
10 October 2019AsiaRory O'Neill

Insilico Medicine signs $200m AI drug discovery deal

Hong Kong-based Insilico Medicine has agreed an artificial intelligence (AI) breast cancer drug discovery partnership worth a potential $200 million with a Chinese pharmaceutical company.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Novartis and BenevolentAI sign AI oncology deal
9 September 2019   Swiss pharmaceutical company Novartis has united with BenevolentAI to aid in the discovery and development of new treatments.
Big Pharma
EU invests €35m into AI cancer diagnostics
10 July 2019   The European Commission has pledged €35 million to promote the development of analysis of health images for cancer diagnostics, based on artificial intelligence.


Editor's picks

AstraZeneca unit faces class-action suit over alleged Soliris monopoly
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

Editor's picks

Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025
Americas
Trouble at the USPTO—Part II: Bracing for impact
13 March 2025
Americas
‘We need the top 50 law firms to stand up’: Will Perkins Coie ignite Trump resistance?
13 March 2025
Americas
Trouble at the USPTO—Part I: Why government cutbacks are making everyone nervous
6 March 2025
Americas
‘Lift as you climb’: Abbott, BMS, Hitachi, LEGO Group counsels explore ‘empowerment’
6 March 2025
Careers
Jones Day adds experienced patent litigators from Weil
4 March 2025

More on this story

Big Pharma
Novartis and BenevolentAI sign AI oncology deal
9 September 2019   Swiss pharmaceutical company Novartis has united with BenevolentAI to aid in the discovery and development of new treatments.
Big Pharma
EU invests €35m into AI cancer diagnostics
10 July 2019   The European Commission has pledged €35 million to promote the development of analysis of health images for cancer diagnostics, based on artificial intelligence.

More on this story

Big Pharma
Novartis and BenevolentAI sign AI oncology deal
9 September 2019   Swiss pharmaceutical company Novartis has united with BenevolentAI to aid in the discovery and development of new treatments.
Big Pharma
EU invests €35m into AI cancer diagnostics
10 July 2019   The European Commission has pledged €35 million to promote the development of analysis of health images for cancer diagnostics, based on artificial intelligence.

More features

South Korean firm sues in UK over CRISPR/Cas9 blood disorder drug
In vivo cell therapy: A world beyond ex vivo engineering
Patent litigator with biotech and medical device background joins Sterlington
Resilience and the power of brands: Elisabeth Stewart-Bradley on 9/11, inclusion and the INTA presidency
Fenwick establishes new Boston office with trio of IP partners from Cooley
How pharma should prep for the six-bill avalanche from Congress
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
USPTO speeds up patent issuance amid widespread agency changes